Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
CTM-N2D-102
Phase 1 mab active
Quick answer
Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D) for Cancer is a Phase 1 program (mab) at CytoMed Therapeutics Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CytoMed Therapeutics Ltd
- Indication
- Cancer
- Phase
- Phase 1
- Modality
- mab
- Status
- active